Physician

Alan Enrique Orellana, M.D.

According to 2025 Medicare claims, Alan Orellana, M.D. (NPI: 1760692248) practices pulmonary disease in the Las Cruces, NM market, with the plurality of this provider's patient population coming from Dona Ana, NM. This provider's primary affiliated billing organization is LUNG SPECIALISTS OF LAS CRUCES, LLC (NPI: 1598192072; TIN: 463761382) and primary practice location at 88011-5049.

Orellana's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 819 traditional Medicare patients, billed 5,727 HCPCS/CPT codes, and received $360,395 in Medicare payments. The top billing code was 99291 (Critical care, first 30-74 minutes). Part D data shows 624 prescription claims across 168 beneficiaries totaling $1,440,525 in drug costs, led by Uptravi (Selexipag). DME data shows 914 claims. Open Payments data shows 29 records totaling $796. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $226,853 to $360,395. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,239,407 and ending at $1,440,525. For DME billing, reported payments moved from a lower plateau to a higher plateau, from $127,732 to $204,322.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	565	2,567	$226,853
2016	608	2,827	$232,236
2017	667	3,188	$217,084
2018	789	4,274	$246,782
2019	677	5,180	$289,810
2020	753	4,798	$338,371
2021	793	5,475	$419,516
2022	811	4,971	$382,783
2023	891	5,977	$439,212
2024	819	5,727	$360,395

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	177	935	$1,239,407
2016	182	1,142	$1,532,066
2017	206	1,084	$1,108,453
2018	240	1,271	$1,456,526
2019	346	2,027	$2,474,473
2020	366	1,736	$1,930,038
2021	229	1,060	$1,304,815
2022	209	1,046	$1,431,197
2023	181	863	$1,253,526
2024	168	624	$1,440,525

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	243	1,413	$205,187
2016	214	1,451	$123,499
2017	192	1,407	$99,725
2018	186	1,366	$127,681
2019	179	1,678	$258,438
2020	272	2,138	$411,968
2021	229	2,116	$405,819
2022	168	1,708	$300,612
2023	148	1,365	$269,388
2024	100	914	$230,994

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99291	Critical care, first 30-74 minutes	207	604	$151
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	461	911	$85
94729	Test to examine how well the lungs exchange gases	424	485	$37
94726	Test to determine lung volumes using sensors	423	484	$36
94060	Test to measure expiratory airflow and volume changes before and after medication administration	434	495	$25

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Uptravi	Selexipag	13	562	$469,905
Nucala	Mepolizumab	50	1,624	$200,994
Opsumit	Macitentan	13	390	$163,234
Pirfenidone	Pirfenidone	13	450	$117,463
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	67	2,910	$61,692

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E0466	Home ventilator, any type, used with non-invasive interface, (e.g., mask, chest shell)	Y	25	165	$161,773
J7677	Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram	N	N/R	37	$31,243
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	42	299	$24,084
E1392	Portable oxygen concentrator, rental	Y	22	140	$5,112
J7606	Formoterol fumarate, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 20 micrograms	N	N/R	19	$2,884

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	29	$796	GlaxoSmithKline, LLC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Alan Enrique Orellana, M.D.?

Tedicare shows public-source Medicare data for Alan Enrique Orellana, M.D. (NPI 1760692248), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alan Enrique Orellana, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Alan Enrique Orellana, M.D.?

Alan Enrique Orellana, M.D. is linked to LUNG SPECIALISTS OF LAS CRUCES, LLC (billing NPI 1598192072) in the available physician profile data.

Does Alan Enrique Orellana, M.D. have Open Payments data?

Alan Enrique Orellana, M.D. has 29 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.